These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23913236)

  • 1. Drug delivery approaches for ovarian cancer therapy.
    Malek A
    Methods Mol Biol; 2013; 1049():437-42. PubMed ID: 23913236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
    Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
    Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
    Tummala MK; Alagarsamy S; McGuire WP
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy.
    Sawicki JA; Anderson DG; Langer R
    Adv Exp Med Biol; 2008; 622():209-19. PubMed ID: 18546630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery.
    Corbin IR
    Methods Mol Biol; 2013; 1049():467-80. PubMed ID: 23913238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
    de Bree E; Rosing H; Michalakis J; Romanos J; Relakis K; Theodoropoulos PA; Beijnen JH; Georgoulias V; Tsiftsis DD
    Eur J Surg Oncol; 2006 Aug; 32(6):666-70. PubMed ID: 16618534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal delivery of nanoparticles for cancer gene therapy.
    Hallaj-Nezhadi S; Dass CR; Lotfipour F
    Future Oncol; 2013 Jan; 9(1):59-68. PubMed ID: 23252564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
    Meredith RF; Buchsbaum DJ; Alvarez RD; LoBuglio AF
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5643s-5645s. PubMed ID: 17875801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock proteins in ovarian cancer: a potential target for therapy.
    Cohen M; Dromard M; Petignat P
    Gynecol Oncol; 2010 Oct; 119(1):164-6. PubMed ID: 20580418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoscale delivery systems for multiple drug combinations in cancer.
    Cao Y; Wang B; Lou D; Wang Y; Hao S; Zhang L
    Future Oncol; 2011 Nov; 7(11):1347-57. PubMed ID: 22044207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?
    Markman M; Francis P; Rowinsky E; Hoskins W
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):84-7. PubMed ID: 7597437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of anticancer drugs.
    Zee-Cheng RK; Cheng CC
    Methods Find Exp Clin Pharmacol; 1989; 11(7-8):439-529. PubMed ID: 2689812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer.
    Liu P; Gou M; Yi T; Qi X; Xie C; Zhou S; Deng H; Wei Y; Zhao X
    Int J Oncol; 2012 Oct; 41(4):1504-12. PubMed ID: 22825572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment outcomes for advanced ovarian cancers with peritoneal dissemination].
    Oe S; Hasegawa K; Ichikawa R; Torii Y; Kato R; Komiyama S; Udagawa Y
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):591-7. PubMed ID: 21498987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.
    Muggia FM
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S18-24. PubMed ID: 17223446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical setting and pharmacology of intraperitoneal chemotherapy: an overview.
    Myers CE
    Semin Oncol; 1985 Sep; 12(3 Suppl 4):12-6. PubMed ID: 4048971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for ovarian cancer.
    Lorusso D; Pietragalla A; Mainenti S; Di Legge A; Amadio G; Scambia G
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):635-52. PubMed ID: 20604741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
    Oestreicher P
    ONS Connect; 2007 Apr; 22(4):24-5. PubMed ID: 17477008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.